Clarification of terminology in drug safety

Drug Safety

Volumn 28, Issue 10, 2005, Pages 851-870

  Aronson, Jeffrey K ^a   Ferner, Robin E ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ACETYLSALICYLIC ACID; ADIPIODONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMOXICILLIN; AMPICILLIN; ANTIHISTAMINIC AGENT; CARBIMAZOLE; CHLOROQUINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIETHYLSTILBESTROL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; EXCIPIENT; HYDRALAZINE; NEUROLEPTIC AGENT; NITRATE; OPIATE; PENICILLIN G; QUININE; SILDENAFIL; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VANCOMYCIN;

BREAST CARCINOMA; CARCINOGENESIS; COLOR VISION DEFECT; CONTROLLED DRUG RELEASE; COUGHING; DESENSITIZATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG NOMENCLATURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HAY FEVER; HEADACHE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS; NAUSEA; NEUTROPENIA; OSTEOPOROSIS; PHOCOMELIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RASH; RETINOPATHY; REVIEW; REYE SYNDROME; SKIN ALLERGY; SLOW RELEASE FORMULATION; SUSTAINED DRUG RELEASE; SYNCOPE; TARDIVE DYSKINESIA; TERATOGENESIS; THROMBOCYTOPENIA; TIMED DRUG RELEASE; VAGINA CANCER; VENOUS THROMBOEMBOLISM; VOMITING; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; HUMANS; PHARMACEUTICAL PREPARATIONS; SAFETY; TERMINOLOGY;

EID: 15944372781     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200528100-00003     Document Type: Review

References (91)

1. Buetow SA, Sibbald B, Cantrill JA, et al. Appropriateness in health care: application to prescribing. Soc Sci Med 1997; 45: 261-71
2. Aronson JK. What is a clinical trial? Br J Clin Pharmacol 2004; 58: 61-3
3. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Commun 2001; L121: 34-44 [online]. Available from URL: http://www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdf [Accessed 2003 Sep 26]
4. Inman WH. Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods. BMJ (Clin Res Ed) 1981; 282: 1131-2.
5. II: Prescription-event monitoring at the University of Southampton. BMJ (Clin Res Ed) 1981; 282: 1216-7
6. Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. I: Background, description, and instructions for use. JAMA 1979; 242: 623-32
7. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29-34
8. Dunn N. 10-minute consultation: adverse drug event. BMJ 2003; 326: 1018
9. World Health Organization. International drug monitoring: the role of national centres. Technical Report Series No 498. Geneva: WHO, 1972
10. Laurence D, editor, Carpenter J, contributor. A dictionary of pharmacology and allied topics. Amsterdam: Elsevier, 1998
11. Stephens MBD, Talbot JCC, Routledge PA, editors. The detection of new adverse drug reactions. 4th ed. London: Macmillan, 1998: 32-44
12. Ferner RE, Aronson JK. Errors in prescribing, preparing, and giving medicines: definition, classification, and prevention. In: Aronson JK, editor. Side effects of drugs. Annual 22. Amsterdam: Elsevier, 1999
13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, classification, diagnosis, management, surveillance. Lancet 2000; 356: 1255-60
14. Hartigan-Go KY, Wong JQ. Inclusion of therapeutic failures as adverse drug reactions. In: Aronson JK, editor. Side effects of drugs. Annual 23. Amsterdam: Elsevier, 2000: xxvii-xxxiii
15. Wayne EJ. Problems of toxicity in clinical medicine. In: Walpole AL, Spinks A, editors. The evaluation of drug toxicity. London: J & A Churchill Ltd, 1958: 1-11
16. Levine RR. Factors modifying the effects of drugs in individuals. In: Pharmacology: drug actions and reactions. Boston (MA): Little, Brown and Co, 1973: 261-91
17. Wade OL, Beeley L. Adverse reactions to drugs. 2nd ed. London: William Heinemann Medical Books Ltd, 1976: Chapter II
18. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977: 44
19. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. 2nd ed. Oxford: Oxford University Press, 1981: 11
20. Grahame-Smith DG, Aronson JK. The Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 1984: 134
21. Hoigné R, Jaeger MD, Wymann R, et al. Time pattern of allergic reactions to drugs. Agents Actions Suppl 1990; 29: 39-58
22. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95
23. Laurence DR, Bennett PN. Clinical pharmacology. Edinburgh: Churchill Livingstone, 1992: 121-2
24. Ferner R, Mann RD. Drug safety and pharmacovigilance. In: Page C, Curtis MJ, Sutter MC, et al., editors. Integrated pharmacology. 1st ed. London: Mosby, 1997: 83-90
25. Aronson JK. Evidence-based medicine and the principles of drug therapy. Chapter 2. In: Haslett C, Chilvers ER, Boon NA, et al., editors. 19th ed. Davidson's textbook of medicine. Edinburgh: Churchill Livingstone, 2002
26. Aronson JK, Ferner RE. Joining the DoTS: classifying adverse drug reactions by dose responsiveness, time course, and susceptibility. BMJ 2003; 327: 1222-5
27. Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ (Clin Res Ed) 1981; 282: 974-6
28. Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. In: Davies DM, Ferner RE, De Glanville H, editors. Davies's textbook of adverse drug reactions. 5th ed. London: Chapman & Hall Medical, 1998: 40
29. Frenz DA. Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology. Ann Allergy Asthma Immunol 2001; 86: 150-7
30. Troisi CL, Heiberg DA, Hollinger FB. Normal immune response to hepatitis B vaccine in patients with Down's syndrome: a basis for immunization guidelines. JAMA 1985; 254: 3196-9
31. Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001; 345: 804-9
32. Friedmann PS, Moss C, Shuster S, et al. Quantitative relationships between sensitising dose of DNCB and reactivity in normal subjects. Clin Exp Immunol 1983; 53: 709-15
33. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. BMJ (Clin Res Ed) 1984; 289: 410-2
34. Smith SE, Rawlins MD. Variability in human drug response. London: Butterworths, 1973
35. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991; 164: 1180-5
36. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30: 55-61
37. Saxon A, Beall GN, Rohr AS, et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987; 107: 204-15
38. Geyman JP, Erickson S. The ampicillin rash as a diagnostic and management problem: case reports and literature review. J Fam Pract 1978; 7: 493-6
39. Li KL, Huang HS, Wang PW, et al. Agranulocytosis associated with anti-thyroid drug in patients with Graves' thyrotoxicosis: report of 11 cases. Changgeng Yi Xue Za Zhi 1991; 14: 168-73
40. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-23
41. Hektoen L. Allergy or anaphylaxis in experiment and disease. JAMA 1912; 58: 1081-8
42. Simpson J, Weiner E, editors. The Oxford English Dictionary. 2nd ed. Oxford: Oxford University Press, 1989
43. Rosenheim ML, Moulton R, editors. Sensitivity reactions to drugs. Oxford: Blackwells Scientific Publications, 1958: 4
44. Hoigné RV. Should "idiosyncrasy" be defined as equivalent to "type B" adverse drug reactions? Pharmacoepidemiol Drug Saf 1997; 6: 213
45. Dorland's Illustrated Medical Dictionary. 30th ed. Philadelphia (PA): Saunders, 2003
46. David TJ. Adverse reactions and intolerance to foods. Br Med Bull 2000; 56: 34-50
47. Venulet J. Monitoring adverse reactions to drugs. In: Jucken E, editor. Progress in drug research. Basle: Berghausen Verlag, 1977
48. Tangrea JA, Adrianza ME, McAdams M. A method for the detection and management of adverse events in clinical trials. Drug Inf J 1991; 25: 63-80
49. Assenzo JR, Sho VS. Use of statistics in the analysis of side-effect data from clinical trials of psychoactive agents. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 543-50
50. Grohmann R, Rütter E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology 1989; 99: S101-4
51. Karch FE, Lasagna L. Adverse drug reactions. JAMA 1975; 234: 1236-41
52. World Health Organization. Letter MIO/372/2(A). Geneva: World Health Organization, 1991
53. Meyboom RHB, Royer RJ. Causality classification at pharmacovigilance centres in the European Community. Pharmacoepidemiol Drug Saf 1992; 1: 87-97
54. Hutchinson TA, Leventhal JM, Kramer MS, et al. An algorithm for the operational assessment of adverse drug reactions. II: Demonstration of reproducibility and validity. JAMA 1979; 242: 633-8
55. Leventhal JM, Hutchinson TA, Kramer MS, et al. An algorithm for the operational assessment of adverse drug reactions. III: Results of tests among clinicians. JAMA 1979; 242: 1991-4
56. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability for adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
57. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 1995; 58: 692-8
58. Stephens MDB. The diagnosis of adverse medical events associated with drug treatment. Adverse Drug React Acute Poisoning Rev 1987; 1: 1-35
59. Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: 374-89
60. Bryant GD, Norman GR. Expressions of probability: words and numbers [letter]. N Engl J Med 1980; 302: 411
61. Kong A, Barnett GO, Mosteller F, et al. How medical professionals evaluate expressions of probability. N Engl J Med 1986; 315: 740-4
62. Calman KC, Royston GDH. Risks language and dialects. BMJ 1997; 315: 939-42
63. Paling J. Strategies to help patients understand risks. BMJ 2003; 327: 745-8
64. Edwards A. Communicating risk through analogies [letter]. BMJ 2003; 327: 749
65. Royal Society Study Group. Risk assessment. London: The Royal Society, 1983
66. Lindquist M, Edwards IR, Bate A, et al. From Association to Alert: a revised approach to international signal analysis. Pharmacoepidemiol Drug Saf 1999; 8: S15-25
67. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-21
68. Orre R, Lansner A, Bate A, et al. Bayesian neural networks with confidence estimations applied to data mining. Comput Stat Data Analysis 2000; 34: 473-93
69. Lindquist M, Ståhl M, Bate A, et al. A retrospective valuation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000; 23: 533-42
70. Jick H. The discovery of drug-induced illness. N Engl J Med 1977; 296: 481-5
71. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. BMJ (Clin Res Ed) 1982; 284: 249-52
72. Kenney RM. Between never and always. N Engl J Med 1981; 305: 1097-8
73. Toogood JH. What do we mean by "usually"? [letter]. Lancet 1980; I: 1094
74. Roberts DE, Gupta G. How medical professionals evaluate expressions of probability [letter]. N Engl J Med 1987; 316: 550
75. Marion MN, Simon P. Signification des adverbes utilisés pour indiquer la frequence des effets secondaires d'un medicament. Thérapie 1984; 39: 4762-3
76. Mapes REA. Verbal and numerical estimates of probability in therapeutic contexts. Soc Sci Med 1979; 13A: 277-82
77. Calman KC. Cancer: science and society and the communication of risk. BMJ 1996; 313: 799-802
78. Wood SM, Coulson R. Adverse Drug Reactions On-line Information Tracking (ADROIT). Pharm Med 1993; 7: 203-13
79. Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf 2002; 25: 445-52
80. Wang AY, Sable JH, Spackman KA. The SNOMED clinical terms development process: refinement and analysis of content. Proc AMIA Symp 2002: 9
81. Council for International Organizations of Medical Sciences. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Saf 1992; 1: 39-45
82. Bankowski Z, Bruppacher R, Crusius I, Gallagher J, Kremer G, Venulet J, editors. Reporting adverse drug reactions: definitions of terms and criteria for their use. Geneva: CIOMS, 1999
83. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109-17
84. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24
85. Herxheimer A. Benefit, risk and harm. Aust Presc 2001; 24: 18
86. Sandercock P, Berge E, Dennis M, et al. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol Assess 2002; 6: 1-112
87. Hunink MG, Bult JR, de Vries J, et al. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998; 18: 337-46
88. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions [online]. Available from URL: http://www.who.int/medicines/library/qsm/who-edm-qsm-2002-2/esd_safety.pdf [Accessed 2003 Sep 26]
89. Orme ML'E. The Debendox saga. BMJ (Clin Res Ed) 1985; 291: 918-9
90. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000; 59: 781-800
91. Delamothe T. Reporting adverse drug reactions. BMJ 1992; 304: 465